Journal article icon

Journal article

CAMPATH: from concept to clinic.

Abstract:

Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chronic lymphocyte leukaemia. Short-term therapy with alemtuzumab has demonstrated long-term benefit in a number of autoimmune conditions. This drug has the potential to facilitate recruitment of tole...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1098/rstb.2005.1702

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Pathology Dunn School
Role:
Author
Journal:
Philosophical transactions of the Royal Society of London. Series B, Biological sciences
Volume:
360
Issue:
1461
Pages:
1707-1711
Publication date:
2005-09-05
DOI:
EISSN:
1471-2970
ISSN:
0962-8436
URN:
uuid:ea30930e-b8c6-4b36-b792-9e3997bfc12f
Source identifiers:
28703
Local pid:
pubs:28703

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP